Evidence map›Paper›PMID 21454522›Full record

ArticleThe Journal of biological chemistry2011

Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans.

Nicola L Beer, Martijn van de Bunt, Kevin Colclough, Christine Lukacs, Paul Arundel, Constance L Chik, Joseph Grimsby, Sian Ellard, Anna L Gloyn

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. The insulin centennial-100 years of milestones in biochemistry.The Journal of biological chemistry · 2021
    Article
  6. Article
  7. Recognition of maturity-onset diabetes of the young in China.Journal of diabetes investigation · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Reclassification of diabetes etiology in a family with multiple diabetes phenotypes.The Journal of clinical endocrinology and metabolism · 2014
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Nicola L BeerOxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, United Kingdom.
Martijn van de Bunt
Kevin Colclough
Christine Lukacs
Paul Arundel
Constance L Chik
Joseph Grimsby
Sian Ellard
Anna L Gloyn
University of Oxford · GBLa Roche College · USNational Health Service · GBOxford Centre for Diabetes, Endocrinology and Metabolism · GBSheffield Children's NHS Foundation Trust · GBUniversity of Alberta · CAUniversity of Exeter · GB

Funding

Medical Research Council 81696Medical Research Council G0700222Medical Research Council G0700222(81696)
6 · The paper itself

Abstract

Type 2 diabetes is a global problem, and current ineffective therapeutic strategies pave the way for novel treatments like small molecular activators targeting glucokinase (GCK). GCK activity is fundamental to beta cell and hepatocyte glucose metabolism, and heterozygous activating and inactivating GCK mutations cause hyperinsulinemic hypoglycemia (HH) and maturity onset diabetes of the young (MODY) respectively. Over 600 naturally occurring inactivating mutations have been reported, whereas only 13 activating mutations are documented to date. We report two novel GCK HH mutations (V389L and T103S) at residues where MODY mutations also occur (V389D and T103I). Using recombinant proteins with in vitro assays, we demonstrated that both HH mutants had a greater relative activity index than wild type (6.0 for V389L, 8.4 for T103S, and 1.0 for wild type). This was driven by an increased affinity for glucose (S(0.5), 3.3 ± 0.1 and 3.5 ± 0.1 mm, respectively) versus wild type (7.5 ± 0.1 mm). Correspondingly, the V389D and T103I MODY mutants had markedly reduced relative activity indexes (<0.1). T103I had an altered affinity for glucose (S(0.5), 24.9 ± 0.6 mm), whereas V389D also exhibited a reduced affinity for ATP and decreased catalysis rate (S(0.5), 78.6 ± 4.5 mm; ATP(K(m)), 1.5 ± 0.1 mm; K(cat), 10.3 ± 1.1s(-1)) compared with wild type (ATP(K(m)), 0.4 ± <0.1; K(cat), 62.9 ± 1.2). Both Thr-103 mutants showed reduced inhibition by the endogenous hepatic inhibitor glucokinase regulatory protein. Molecular modeling demonstrated that Thr-103 maps to the allosteric activator site, whereas Val-389 is located remotely to this position and all other previously reported activating mutations, highlighting α-helix 11 as a novel region regulating GCK activity. Our data suggest that pharmacological manipulation of GCK activity at locations distal from the allosteric activator site is possible.

Indexed as

GlucokinaseHyperinsulinismHypoglycemiaMutation, MissenseAllosteric RegulationAmino Acid SubstitutionChild, PreschoolDiabetes Mellitus, Type 2HumansInfant, NewbornLiverMaleProtein Structure, SecondaryGlucokinase

Identifiers

PMID21454522
PMCPMC3099725
OpenAlexW2126503833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.